Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab-Reference-Cited by-同舟云学术

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab

Published:2023-12-14 Issue:1 Volume:32 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Laheij A. M. G. A.^ORCID,van de Donk N. W. C. J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-023-08233-0.pdf

Reference18 articles.

1. Tan S, Li D, Zhu X (2020) Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother 124:109821

2. Chari A et al (2022) Talquetamab, A T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232–2244

3. Mueller C et al (2003) Quantitative assessment of gustatory function in a clinical context using impregnated "taste strips". Rhinology 41(1):2–6

4. Epstein JB et al (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30(11):785–792

5. Navazesh M, Kumar SK (2008) Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 139(Suppl):35s–40s

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

2. Dermatologische Toxizitäten von Talquetamab, einem neuen bispezifischen Antikörper: Fallserie und Literaturübersicht;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-09

3. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma;Current Hematologic Malignancy Reports;2024-08-15

4. Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-08-02

5. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab;eJHaem;2024-07-03